



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo

Citation for published version:

Semple, F, Webb, S, Li, H-N, Patel, HB, Perretti, M, Jackson, IJ, Gray, M, Davidson, DJ & Dorin, J 2010, 'Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo', *European Journal of Immunology*, vol. 40, no. 4, pp. 1073-1078. <https://doi.org/10.1002/eji.200940041>

Digital Object Identifier (DOI):

[10.1002/eji.200940041](https://doi.org/10.1002/eji.200940041)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

European Journal of Immunology

Publisher Rights Statement:

Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Human β -defensin 3 has immunosuppressive activity *in vitro* and *in vivo*

Fiona Semple¹, Sheila Webb¹, Hsin-Ni Li², Hetal B. Patel³,
Mauro Perretti³, Ian J. Jackson¹, Mohini Gray², Donald J. Davidson²
and Julia R. Dorin¹

¹ MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XU, Scotland, UK

² Centre for Inflammation Research, QMRI University of Edinburgh UK

³ William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London UK

β -defensins are antimicrobial peptides with an essential role in the innate immune response. In addition β -defensins can also chemoattract cells involved in adaptive immunity. Until now, based on evidence from dendritic cell stimulation, human β defensin-3 (hBD3) was considered pro-inflammatory. We present evidence here that hBD3 lacks pro-inflammatory activity in human and mouse primary M ϕ . In addition, in the presence of LPS, hBD3 and the murine orthologue Defb14 (but not hBD2), effectively inhibit TNF- α and IL-6 accumulation implying an anti-inflammatory function. hBD3 also inhibits CD40/IFN- γ stimulation of M ϕ and *in vivo*, hBD3 significantly reduces the LPS-induced TNF- α level in serum. Recent work has revealed that hBD3 binds melanocortin receptors but we provide evidence that these are not involved in hBD3 immunomodulatory activity. This implies a dual role for hBD3 in antimicrobial activity and resolution of inflammation.

Key words: Anti-inflammatory · cAMP · Defensin · TNF- α



Supporting Information available online

Introduction

β -defensins are broad spectrum, cationic, antimicrobial peptides. They are expressed predominantly at mucosal surfaces and believed to be important components of innate immunity although their precise *in vivo* role has not been clarified [1]. Human β -defensins are a multigene family and the main cluster on chromosome 8p23 has been shown to be copy number variable [2]. Increased copy number in humans is associated with psoriasis and decreased copy number with Crohn's disease, suggesting involvement in these autoimmune diseases [3, 4]. Human β defensin-3 (hBD3) is one of the most cationic of the β -defensins with broad spectrum, salt

insensitive, antimicrobial activity [5]. It is highly expressed in psoriatic skin and the reproductive tract [6, 7]. Defensins have been considered pro-inflammatory as their expression increases in response to TLR ligands, TNF- α , IL-1 β , IFN- γ and PMA, and following infection or injury [5, 8, 9]. In addition, they have been shown to chemoattract CD4 T cells and immature dendritic cells through CCR6, suggesting that they link innate and adaptive immunity [10]. hBD3 and 4 also chemoattract monocytes and M ϕ [8, 11], and hBD3 has been shown to activate monocytes and myeloid dendritic cells through TLR-1/2 by inducing expression of co-stimulatory molecules and NF- κ B [12]. Recently, human α -defensins present in neutrophil granules have been shown to display anti-inflammatory properties [13].

In this paper we show that hBD3 does not induce TNF- α or IL-6 in M ϕ and in fact has potent anti-inflammatory effects on both human and mouse primary M ϕ . The anti-inflammatory effect was also

Correspondence: Dr. Fiona Semple
e-mail: fsemple@hgu.mrc.ac.uk

evident *in vivo* and in the THP-1 human monocytic cell line and RAW264.7 mouse M ϕ cell line. hBD3 effectively inhibited the inflammatory effects of both LPS and CD40 ligand (CD40L). Recently it has been shown that hBD3 can interact with melanocortin receptors *in vitro* [14] and a dominant mutation in this gene in dogs and arctic wolves is causative for black coat colour [15]. Despite melanocortin 1 receptor (MC1R) and melanocortin 3 receptor (MC3R) being expressed on M ϕ and having known immunomodulatory activity, we show here that these receptors do not mediate the novel, potent anti-inflammatory effect displayed by hBD3.

Results and discussion

hBD3 is anti-inflammatory *in vitro*

In contrast to the assumed pro-inflammatory effect of hBD3 summarised above, we show here that synthetic hBD3 inhibits production of TNF- α by the human myelomonocytic cell line THP-1 in a concentration-dependent manner (Fig. 1A). The effect was maximal at 2.5 μ g/mL, and comparable in magnitude to the cationic antimicrobial peptide LL37, which is a known immunomodulatory peptide [16–18]. This same effect was also evident using human peripheral blood monocyte derived M ϕ (Fig. 1B).

Treatments did not affect cell viability as MTT assay measurements were comparable between treated cells and untreated controls.

Addition of hBD3 to the mouse M ϕ cell line RAW264.7 also led to inhibition of TNF- α and IL-6 production (Fig. 1C and D). In our experimental settings hBD3 did not induce TNF- α or IL-6, in contrast to the recent report that this defensin activates monocytes and myeloid dendritic cells *via* TLR1/2, up-regulating the co-stimulatory molecules CD80, CD86 and CD40 [12]. We observe our anti-inflammatory effect with 5 μ g/mL ($\sim 1 \mu$ M) of synthetic hBD3 by directly measuring the attenuation of pro-inflammatory cytokine production, whereas Funderburg *et al* observe their effects on co-stimulatory molecules with 20 μ g/mL of recombinant hBD3 (and do not measure pro-inflammatory cytokines). We did, however, observe a slight increase in TNF- α with hBD3 at 10 μ g/mL but only in RAW264.7 cells (Fig. 1D), not primary M ϕ or THP-1 cells, suggesting that in specific cells at higher concentrations of hBD3 there may also be a pro-inflammatory effect of hBD3.

The anti-inflammatory effect of both hBD3 and the mouse orthologue Defb14 [19] was observed in mouse primary BM-derived M ϕ (BMDM), reducing the TNF- α response to LPS (Fig. 1E). hBD2 was not an effective suppressor of the TNF- α response to LPS in mouse cells (Fig. 1E), whereas hBD3 was more effective than LL37 in all mouse strains tested (Fig. 1F). hBD2 has only approximately




Figure 1. hBD3 down-regulates cytokine production in response to the TLR4 agonist LPS in human and mouse M ϕ . (A) THP-1 monocyte cell line, (B) human monocyte-derived M ϕ , (C and D) RAW264.7 mouse M ϕ cell line and (E) BMDM from CBA mice were exposed to β -defensin or control peptides at 5 μ g/mL, in the presence or absence of LPS for 18 h in serum-free media. TNF- α (or IL-6) in the supernatant was measured by ELISA, $n = 6$ donors for the human primary cells, $n = 3$ THP-1, $n = 3$ RAW264.7 and $n = 3$ mouse BMDM (from three separate mice). Figure shows means \pm SEM, significance assessed by two-way ANOVA, *** $p < 0.001$, ** $p < 0.01$ was calculated by comparing LPS plus peptide to LPS alone. (F) TNF- α levels in supernatant in BMDM from different mouse strains, treated with hBD3 or LL37 at indicated concentrations, with and without LPS for 18 h, $n = 3$. Statistical comparisons are between LPS alone versus LPS with peptide in each strain, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$.

30% amino acid similarity to hBD3, which may explain lack of anti-inflammatory effects. Conversely, Defb14, which is 64% identical to hBD3 [20], did demonstrate anti-inflammatory activity.

The anti-endotoxic effects of LL37 have been shown to be partly due to direct binding of LL37 to LPS [16, 21]. It has previously been shown that hBD3 does not inhibit endotoxin binding in a Limulus assay [22] and we confirmed this finding (Supporting Information) to demonstrate similar endotoxin activity in the presence and absence of hBD3. However, the Limulus assay is not a direct measure of LPS-hBD3 binding; so we also investigated hBD3 effects after LPS stimulation of cells. Figure 2A shows that TNF- α levels were significantly reduced even when hBD3 was added to M ϕ 1 h after LPS. This suggests that even if hBD3 binds LPS to some extent, most of the hBD3 inhibitory effect is occurring downstream of TLR4 activation by LPS.

Further evidence that hBD3 is endowed with general anti-inflammatory properties is shown in Fig. 2B. Stimulation with IFN- γ and CD40L results in M ϕ activation and increased TNF- α , but here we show that hBD3 inhibited this pro-inflammatory cytokine response in mouse BMDM. This effect was also evident in C3H/HeJ M ϕ , which lack functional TLR4, demonstrating that hBD3 is not simply inhibiting stimulation by endotoxin contamination. The anti-inflammatory effect was not evident when cells were exposed to PAM₃CSK₄ a TLR1/2 agonist (Fig. 2C). This suggests that hBD3 has an effect on signalling molecules that are used by TLR4 and CD40 but not TLR1/2. This differs from LL-37, which has been shown to inhibit pro-inflammatory responses *via* both TLR4 and

TLR1/2. [16]. As TLR4 and TLR1/2 signalling both involve MyD88 it is possible that hBD3 is affecting components of the non-MyD88 pathway (such as TRAM and TRIF) downstream of TLR4.

hBD3 is anti-inflammatory *in vivo*

Next, we wished to see whether hBD3 could reduce the accumulation of TNF- α in mice following exposure to LPS. We injected 16 mg/kg LPS into male Balb/c mice with and without 10 μ g of hBD3 and measured serum TNF- α levels 1 h later. We found that the group injected with hBD3 and LPS had significantly reduced levels of TNF- α compared with mice receiving LPS alone (Fig. 2D). This result demonstrates that hBD3 inhibits LPS-stimulated TNF- α production *in vivo* as well as *in vitro*. The extent of inhibition afforded by hBD3 was comparable to that conferred by 1 μ g IL-10, which protects mice from endotoxic shock [23], so hBD3 may provide similar protection.

Melanocortin receptors are not involved in hBD3 anti-inflammatory function

hBD3 is a promiscuous ligand which interacts with CCR6 and another unknown M ϕ receptor [14, 24]. In addition, Candille *et al* elegantly show that overexpressing the dog orthologue of hBD3




Figure 2. Dissection of hBD3 anti-inflammatory function and *in vivo* effects of hBD3. (A) The mouse M ϕ cell line RAW 264.7 was exposed at various times up to 1 h with LPS before treatment with hBD3, followed by 18 h incubation. The inhibitory effect was still evident at all time points ($n = 2$, $*p < 0.05$). (B) BMDM from different mouse strains were activated with CD40L (5 μ g/mL) and IFN- γ (5 ng/mL) (CI) with and without hBD3 for 18 h. TNF- α levels in supernatants were measured. BMDM were prepared from at least three separate mice for each strain. Statistical comparisons are between agonist alone versus agonist with hBD3 within each strain, $**p < 0.01$ by two-way ANOVA. (C) TNF- α levels in supernatant in BMDM from different mouse strains, treated with hBD3 at indicated concentrations, with and without Pam₃Csk₄ for 18 h, $n = 3$. (D) Balb/c male mice were injected i.p. with 16 mg/kg LPS with or without 10 μ g hBD3 in 200 μ L saline. After 1 h animals were killed and exsanguinated and serum TNF- α measured. Figure shows means \pm SEM and comparison between LPS alone ($n = 18$) and LPS with hBD3 ($n = 21$) is statistically different $*p = 0.032$ by unpaired t-test.

alters hair colour in transgenic mice *via* binding to murine MC1R [14]. We tested whether hBD3 might mediate its anti-inflammatory effect through MC1R or MC3R, as these receptors are expressed in M ϕ , and the known ligand α -melanocortin stimulating hormone is an anti-inflammatory mediator [25]. The absence of either receptor has also been reported to influence the response to inflammatory agents [26, 27]. We tested the naturally defective *Mc1r* mutant mouse strain (recessive yellow *Mc1r^e*) [28] and an *Mc3r* knockout mouse [29]. We found no statistically significant difference between the ability of hBD3 to reduce TNF- α levels following stimulation of TLR4 or CD40 in BMDM from WT controls or mutant mice (Fig. 3A and B). This demonstrates that the anti-inflammatory properties of hBD3 are not mediated by MC1R or MC3R.

hBD3 Anti-inflammatory effect is not mediated by IL-10 or cAMP

IL-10 is a well-known anti-inflammatory cytokine that inhibits co-stimulatory molecule expression on M ϕ and limits the production of pro-inflammatory cytokines and chemokines [30]. We investigated the ability of hBD3 to induce IL-10 in BMDM and established that IL-10 levels were not altered by hBD3 in the presence or absence of LPS (Fig. 3C), suggesting that the hBD3 anti-inflammatory effect is not mediated by IL-10.

cAMP is an important controller of the innate immune system, with a wide range of functions including up-regulation of IL-10 and reduction of TNF- α [31]. Using the membrane permeable cAMP analogue, 8-Bromoadenosine-cAMP (8Br-cAMP), we

examined similarities between cAMP and hBD3 anti-inflammatory activity. TNF- α levels induced by LPS were markedly reduced by 8Br-cAMP or hBD3 alone, however a combination of 8Br-cAMP and hBD3 reduced TNF- α levels further. This effect was evident at low concentrations of hBD3, where hBD3 alone shows minimal inhibition of TNF- α (Fig. 3D). Similarly induction of IL-10 by 8Br-cAMP was inhibited by hBD3 (Fig. 3C). These results suggest that cAMP and hBD3 act through distinct mechanisms.

Concluding remarks

In conclusion, hBD3 is a potent inhibitor of the accumulation of pro-inflammatory cytokines TNF- α and IL-6, secreted in response to the TLR4 agonist LPS and following activation with CD40L. This effect was not due to direct peptide binding of LPS and was not mediated through the anti-inflammatory receptors MC1R or MC3R. In support of this finding hBD3 anti-inflammatory action was independent of cAMP levels and not controlled by an increase in IL-10. In addition, administration of hBD3 to mice reduced LPS-induced serum levels of TNF- α , indicating that hBD3 may be important in controlling inflammation and septic shock. The copy number variation of β -defensins at the 8p23 cluster may lead to subtle variation in expression levels in the human population [2]. Up-regulation of hBD3 is critical to antimicrobial activity in the epithelia; however, the novel hBD3 functions presented here suggest a role in the resolution of inflammation, which is necessary to avoid tissue damage by effectors of antimicrobial action.




Figure 3. hBD3 anti-inflammatory effect does not act through MC1R or MC3R and has mechanisms distinct from cAMP. BMDM from (A) MC1R mutant and (B) MC3R mutant were stimulated with LPS alone or LPS in combination with hBD3 or DefB14 (5 μ g/mL) or (B only) CD40/IFN- γ (CI) alone or in combination with hBD3 as described. After 18 h, concentrations of TNF- α in the supernatants were measured, $n = 3$. Statistical comparisons are between LPS alone versus LPS with peptide in each strain, *** $p < 0.001$, ** $p < 0.01$ by two-way ANOVA. BMDM from Balb/c mice were cultured with LPS (50 ng/mL) in the presence of 8Br-cAMP (100 μ M) and decreasing concentrations of hBD3, as shown, for 18 h. Concentrations of (C) IL-10 and (D) TNF- α in the supernatants were measured by ELISA.

Materials and methods

Reagents

Ultra pure LPS from *E. coli* 0111:B4, Pam₃CSK₄ and IFN- γ were purchased from InvivoGen (San Diego, USA), pertussis toxin, polymixin B and 8Br-cAMP (B7880) from Sigma Dorset, UK and QCL-1000[®] Endpoint Chromogenic LAL Assay from Lonza Group, Basel, Switzerland. Mouse CD40L was kindly provided by Dr. David Gray (University of Edinburgh). hBD3 (GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK) and hBD2 (GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP) were purchased from Peptides International Louisville, USA and are oxidised so the disulfide connectivities are of the canonical β -defensin arrangement [32]. Defb14 (FLPKTLRKFFCRIRGGRCVNLNCLGKEEQIGRCSNSGRKCCRKKK) and LL37 (LLGDFFRKSKKEIGKEFKRIVQRIKDFLRNLVPRTES) were synthesized as previously described [20, 33].

Cells and mice

RAW264.7 cells were maintained in DMEM (GIBCO Paisley, UK) and THP-1 cells in RPMI containing 10% FBS, essential amino acids and antibiotics. Balb/c, CBA and C57 Black/6 mice were obtained from Charles River (UK) and *Mc1r e/e* and *Mc3r* KO mutants were bred in-house. C3H/HeJ *OlaHsd-Tlr4* mutants and C3H/HeN controls were obtained from Harlan Laboratories, UK. Primary M ϕ were generated from femur BM and grown in DMEM containing 10% FBS and 20 ng/mL M-CSF (R&D Systems, Abingdon, UK) for 7 days. Cells were seeded at 1.25×10^5 into 48-well plates and grown without growth factor for 24 h prior to treatment. Replicate experiments were done with separate M ϕ preparations from at least three mice for each experiment.

Human PBMC preparation

Human venous blood was collected according to Lothian Research Ethics Committee approvals #08/S1103/38, using sodium citrate anticoagulant (Phoenix Pharma, Gloucester, UK), and cells were separated by Dextran sedimentation, followed by discontinuous, isotonic Percoll gradient centrifugation as previously described [33]. PBMC were incubated at 4×10^6 /mL in IMDM (PAA Laboratories, Somerset, UK) at 37°C, 5% CO₂, for 1 h. Non-adherent cells were removed and adherent monocytes cultured for 6 days in IMDM with 10% autologous serum to generate monocyte-derived M ϕ .

Cell treatment and ELISA

Cells were treated with LPS (50 ng/mL), Pam₃CSK₄ (100 ng/mL), CD40L (3 μ g/mL) IFN- γ (5 ng/mL), hBD3, Defb14, LL-37, 8Br-cAMP (at concentrations shown) or combinations of these as

described, in serum free media then incubated at 37°C, 5% CO₂ for 18 h. Supernatants were collected and centrifuged to remove particulate debris. Levels of TNF- α , IL-6 and IL-10 in the supernatants were measured using human or mouse DuoSet ELISA (R&D Systems) according to the manufacturer's instructions. Cell viability was measured using TACS[™] MTT assay (R&D Systems).

LPS delivery in vivo

Balb/c male mice (5–8 wk) were injected with 16 mg/kg of LPS (approx. 200 μ g/mouse) with or without 10 μ g of hBD3 in 200 μ L of PBS. After 1 h mice were killed by cervical dislocation, exsanguinated and serum TNF- α levels measured by ELISA. All experiments were covered by Project License PPL 60/3787 granted by the Home Office under the Animal Scientific Procedures Act 1986, and locally approved by the University of Edinburgh Ethical Review Committee.

Statistical analysis

GraphPad Prism 5 statistical software was used to determine statistical significance. One or two-way ANOVA with Bonferroni's multiple comparison post-tests were performed. Where appropriate, statistical significance was determined by an unpaired *t*-test using GraphPad software. For all statistical analyses *p* < 0.05 was considered significant. Values are expressed as mean \pm SEM.

Acknowledgements: The authors thank Kay Samuel, New Royal Infirmary Edinburgh, UK, for FACS analysis and Dr Dominic Campopiano, School of Chemistry, University of Edinburgh, UK for helpful discussion. This work was supported by the MRC and grants from EPSRC (J.R.D.), ARC (M.G.) and D.J.D. is a Wellcome Trust Research Career Development Fellow (Fellowship # 078265).

Conflict of interest: The authors declare no financial or commercial conflict of interest.

References

- Lai, Y. and Gallo, R. L., AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. *Trends Immunol.* 2009. **30**: 131–141.
- Hollox, E. J., Armour, J. A. and Barber, J. C., Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. *Am. J. Hum. Genet.* 2003. **73**: 591–600.
- Hollox, E. J., Huffmeier, U., Zeeuwen, P. L., Palla, R., Lascorz, J., Rodijk-Olthuis, D., van de Kerkhof, P. C. et al., Psoriasis is associated with increased beta-defensin genomic copy number. *Nat. Genet.* 2008. **40**: 23–25.
- Fellermann, K., Stange, D. E., Schaeffeler, E., Schmalzl, H., Wehkamp, J., Bevins, C. L., Reinisch, W. et al., A chromosome 8 gene-cluster polymorph-

- ism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. *Am. J. Hum. Genet.* 2006. **79**: 439–448.
- 5 Harder, J., Bartels, J., Christophers, E. and Schroder, J. M., Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. *J. Biol. Chem.* 2001. **276**: 5707–5713.
 - 6 Gambichler, T., Skrygan, M., Tomi, N. S., Othlinghaus, N., Brockmeyer, N. H., Altmeyer, P. and Kreuter, A., Differential mRNA expression of antimicrobial peptides and proteins in atopic dermatitis as compared to psoriasis vulgaris and healthy skin. *Int. Arch. Allergy Immunol.* 2008. **147**: 17–24.
 - 7 Semple, C. A., Rolfe, M. and Dorin, J. R., Duplication and selection in the evolution of primate beta-defensin genes. *Genome Biol.* 2003. **4**: R31.
 - 8 Garcia, J. R., Jaumann, F., Schulz, S., Krause, A., Rodriguez-Jimenez, J., Forssmann, U., Adermann, K. et al., Identification of a novel, multifunctional beta-defensin (human beta- defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of *Xenopus* oocytes and the induction of macrophage chemoattraction. *Cell Tissue Res.* 2001. **306**: 257–264.
 - 9 Jia, H. P., Schutte, B. C., Schudy, A., Linzmeier, R., Guthmiller, J. M., Johnson, G. K., Tack, B. F. et al., Discovery of new human beta-defensins using a genomics-based approach. *Gene* 2001. **263**: 211–218.
 - 10 Yang, D., Chertov, O., Bykovskaia, S. N., Chen, Q., Buffo, M. J., Shogan, J., Anderson, M. et al., Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science* 1999. **286**: 525–528.
 - 11 Garcia, J. R., Krause, A., Schulz, S., Rodriguez-Jimenez, F. J., Kluver, E., Adermann, K., Forssmann, U. et al., Human beta-defensin 4: a novel inducible peptide with a specific salt- sensitive spectrum of antimicrobial activity. *FASEB J.* 2001. **15**: 1819–1821.
 - 12 Funderburg, N., Lederman, M. M., Feng, Z., Drage, M. G., Jadowsky, J., Harding, C. V., Weinberg, A. and Sieg, S. F., Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. *Proc. Natl. Acad. Sci. USA* 2007. **104**: 18631–18635.
 - 13 Miles, K., Clarke, D. J., Lu, W., Sibinska, Z., Beaumont, P. E., Davidson, D. J., Barr, T. A. et al., Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins. *J. Immunol.* 2009. **183**: 2122–2132.
 - 14 Candille, S. I., Kaelin, C. B., Cattanach, B. M., Yu, B., Thompson, D. A., Nix, M. A., Kerns, J. A. et al., A beta-Defensin mutation causes black coat color in domestic dogs. *Science* 2007. **318**: 1418–1423.
 - 15 Anderson, T. M., von Holdt, B. M., Candille, S. I., Musiani, M., Greco, C., Stahler, D. R., Smith, D. W. et al., Molecular and evolutionary history of melanism in North American gray wolves. *Science* 2009. **323**: 1339–1343.
 - 16 Mookherjee, N., Brown, K. L., Bowdish, D. M., Doria, S., Falsafi, R., Hokamp, K., Roche, F. M. et al., Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. *J. Immunol.* 2006. **176**: 2455–2464.
 - 17 Di Nardo, A., Braff, M. H., Taylor, K. R., Na, C., Granstein, R. D., McInturf, J. E., Krutzik, S. et al., Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. *J. Immunol.* 2007. **178**: 1829–1834.
 - 18 Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D. and Hancock, R. E., The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J. Immunol.* 2002. **169**: 3883–3891.
 - 19 Semple, C. A., Maxwell, A., Gautier, P., Kilanowski, F. M., Eastwood, H., Barran, P. E. and Dorin, J. R., The complexity of selection at the major primate beta-defensin locus. *BMC Evol. Biol.* 2005. **5**: 32.
 - 20 Taylor, K., Clarke, D. J., McCullough, B., Chin, W., Seo, E., Yang, D., Oppenheim, J. et al., Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta -defensin 3. *J. Biol. Chem.* 2008. **283**: 6631–6639.
 - 21 Molhoek, E. M., den Hertog, A. L., de Vries, A. M., Nazmi, K., Veerman, E. C., Hartgers, F. C., Yazdanbakhsh, M. et al., Structure-function relationship of the human antimicrobial peptide LL-37 and LL-37 fragments in the modulation of TLR responses. *Biol. Chem.* 2009. **390**: 295–303.
 - 22 Motzkus, D., Schulz-Maronde, S., Heitland, A., Schulz, A., Forssmann, W. G., Jubner, M. and Maronde, E., The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. *FASEB J.* 2006. **20**: 1701–1702.
 - 23 Howard, M., Muchamuel, T., Andrade, S. and Menon, S., Interleukin 10 protects mice from lethal endotoxemia. *J. Exp. Med.* 1993. **177**: 1205–1208.
 - 24 Wu, Z., Hoover, D. M., Yang, D., Boulegue, C., Santamaria, F., Oppenheim, J. J., Lubkowski, J. and Lu, W., Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. *Proc. Natl. Acad. Sci. USA* 2003. **100**: 8880–8885.
 - 25 Catania, A., Gatti, S., Colombo, G., and Lipton, J. M., Targeting melanocortin receptors as a novel strategy to control inflammation. *Pharmacol. Rev.* 2004. **56**: 1–29.
 - 26 Li, D. and Taylor, A. W., Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages. *J. Leukoc. Biol.* 2008. **84**: 191–198.
 - 27 Getting, S. J., Lam, C. W., Chen, A. S., Grieco, P. and Perretti, M., Melanocortin 3 receptors control crystal-induced inflammation. *FASEB J.* 2006. **20**: 2234–2241.
 - 28 Robbins, L. S., Nadeau, J. H., Johnson, K. R., Kelly, M. A., Roselli-Rehffuss, L., Baack, E., Mountjoy, K. G., and Cone, R. D., Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. *Cell* 1993. **72**: 827–834.
 - 29 Chen, A. S., Marsh, D. J., Trumbauer, M. E., Frazier, E. G., Guan, X. M., Yu, H., Rosenblum, C. I. et al., Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. *Nat. Genet.* 2000. **26**: 97–102.
 - 30 Moore, K. W., de Waal, M. R., Coffman, R. L. and O'Garra, A., Interleukin-10 and the interleukin-10 receptor. *Annu. Rev. Immunol.* 2001. **19**: 683–765.
 - 31 Peters-Golden, M., Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. *Sci. Signal.* 2009. **2**: e37.
 - 32 Chino, N., Kubo, S., Nishio, H., Nishiuchi, Y., Nakazato, M. and Kimura, T., Chemical synthesis of human beta defensin (hBD) -1,-2,-3,-4. Optimisation of the oxidative folding reaction. *Int. J. Peptide Res. Therapeutics* 2006. **12**: 203–209.
 - 33 Barlow, P. G., Li, Y., Wilkinson, T. S., Bowdish, D. M., Lau, Y. E., Cosseau, C., Haslett, C. et al., The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. *J. Leukoc. Biol.* 2006. **80**: 509–520.
- Abbreviations:** 8Br-cAMP: 8-Bromoadenosine-cAMP · BMDM: BM-derived Mφ · CD40L: CD40 ligand · hBD3: human β defensin-3 · MC1R: melanocortin 1 receptor · MC3R: melanocortin 3 receptor
- Full correspondence:** Dr. Fiona Semple, MRC Human Genetics Unit, Western General Hospital, Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XU, Scotland, UK
 Fax: +44-131-467-8456
 e-mail: fsemple@hgu.mrc.ac.uk

Received: 6/10/2009
 Revised: 14/12/2009
 Accepted: 13/1/2010
 Accepted article online: 26/1/2010